Continued excellence in delivering value and results is what drives us every day at Globapharm
about us
PHARMACEUTICAL, DIAGNOSTIC AND MEDICAL DEVICES
Globapharm was established in Australia to assist the healthcare industry to obtain access to innovative medicines and healthcare products. We work closely with our valued partners to bring medicines and products to those that need them most.
Local and INTERNATIONAL NETWORk partnerships
Globapharm is well placed to provide solutions for all its partners. We utilise our Australian and International contact networks to identify pharmaceutical, diagnostic and medical devices which can be successfully registered and supplied to the AUS, NZ and other markets.
proven healthcare experience
With over 80 years of proven cumulative healthcare experience of its key personnel, Globapharm is well placed to help its partners not only meet but surpass their business objectives.
Our team
JeanClaude Balducci
Co-Founder, Business Development Director
Jean Claude has over 30 years of experience driving sales growth in the Pharmaceutical industry (Pharmaceutical products, Medical Device Class I, II, III, Diagnostic tests and OTC products). He has strong International experience having held several senior positions in sales and marketing with Sanofi in France, Latin America and in Australia where he has resided for the last 20 years.
As co-founder of Globapharm, Jean Claude has been able to provide Australian and International Pharmaceutical companies with new Pharmaceutical products and Medical Devices from Europe and the US. He developed the go-to-market strategy for the new Australian affiliate of a European company whilst helping several Australian Pharmaceutical companies find new partners in Europe, Asia and the US for their Australian products.
Jean-Claude’s previously worked for 10 years as Country Manager in the Pharmaceutical industry in Australia & New Zealand, where he was able to identify new products (Medical Devices Diagnostic tests and pharmaceutical products) from Europe, Asia and USA in order to increase the sales and profits of his company. He is adept in revenue and profit generation, resource allocation, development of effective strategies and implementation by the teams, launching new products, team leadership and product development, development of strong relationships with decision makers and HCP Associations.
Theo Antonopoulos
Co-Founder
Theo has over 20 years proven experience, in both frontline and executive level management across the Australian Healthcare system, Pharmaceutical industry and MedTech industry. Theo has always worked in and around the provision of healthcare, having worked as a biochemist at one of Australia’s busiest public hospitals for many years then forged a successful career at both Sanofi Australia and GSK Australia, leading successful teams across Diabetes, Oncology, Haematology, Rare diseases and Pandemic planning.
Theo has been leading teams for over 15 years, teams that have successfully licensed, registered and launched numerous pharmaceutical medicines in Australia and has led transformational projects across the South-East Asian region whilst at GSK. Theo’s previous position was as EGM of Commercial for a leading ASX listed MedTech company based in Australia, where he was successful in delivering 4-year CAGR of +37% whilst supporting the business in its expansion into the US, UK and SEA in more recent times.
Today, Theo works for Globapharm as a consultant. Working closely with the broader team, he works with local and international healthcare clients to find products that complement and/or expand their existing portfolios.
Dr David Harle
Medical Director
David has over 30 years of experience working in the pharmaceutical industry, with broad ranging managerial expertise in marketing, product launch, strategic regulatory affairs, clinical research, pharmacovigilance, QA and business development. He has a proven track record in the successful registration and marketing support (including development and review of promotional material) for a wide range of products in Australia and New Zealand including prescription medicines, biosimilars, Medical Devices including Class I, II and III as well as Diagnostic tests and OTC products across a broad range of therapeutic areas for both large and small pharmaceutical companies including Sandoz (a division of Novartis), Knoll, 3M Pharmaceuticals as well as several small niche pharmaceutical companies.
David has extensive experience in the management of clinical trials across a broad range of therapeutic areas which includes strong international experience having held several senior positions including VP Clinical Operations and VP Business Development (Rest of World Region) as well as Managing Director for the Australian and New Zealand operations of ICON Clinical Research, a leading global Clinical Research Organisation (CRO). In these roles, David was fully responsible for the P&L of the respective departments and for bringing in new business at both the local and global levels.
As Medical Director of Globapharm, David supports Jean-Claude Balducci and Theo with product assessment, regulatory and marketing expertise with new products including therapeutic goods and medical devices for the Australian, New Zealand & International markets. He sits on the Board of two biopharmaceutical companies that are developing novel treatments for pancreatic cancer and NSCLC. David has authored 26 publications in journals including The Lancet and British Medical Journal.
Philip Rafter
Finance Director
Philip has over 20 years’ experience in the Australian accounting and finance market in a number of roles. Philip spent over 10 years in the taxation and professional advice sector working for a number of Chartered Accounting firms. During this time Philip provided professional advice ranging from company taxation to superannuation to general business practices.
Philips clients ranged in size from individuals to companies to superannuation funds to more complex groups. These clients also operated in a variety of industries including Pharmacists and Pharmaceutical companies. It was during this period where he developed an interest in assisting entities in the Medical and Pharmaceutical industry. Philip left the taxation and professional advice sector to work directly for a Pharmaceutical company. Philip has occupied the roles of Financial Controller to Finance Manager to Country Manager over the 10+ years he worked directly for Pharmaceutical companies.
Today, Philip works for Globapharm as the Finance Director. Working closely with the other directors, he is responsible for the company’s financial health by managing the accounting and financial control functions.
Globapharm places great importance in its ability to establish, nurture and evolve its local and global partnerships. It is these partnerships which allows Globapharm to deliver value to its partners in a timely manner.
News
endometriosis diagnostic test
June, 2023
Globapharm is pleased to announce it’s distribution agreement with Endosure Inc, the only FDA-cleared non-invasive, 30-Minute Clinical Decision Support Tool supporting the Highly Accurate and Rapid Diagnosis of Endometriosis. Globapharm has exclusive rights for Australia and New Zealand
portable telemedicine station
April, 2023
Globapharm is pleased to announce it’s distribution agreement with Parsys Telemedicine. Parsys Telemedicine provides mobile, secure and intuitive telemedicine solutions for patients and healthcare professionals. Globapharm has exclusive rights to Parsys suite of Products for the Oceania region.
Dibucell WOUND CARE
August, 2022
Globapharm is pleased to announce its distribution agreement with Celther Polska. Celther Polska commercialises innovative wound care dressings around the world and Globapharm was chosen to seek regulatory approval and lead the commercial launch in Australia and New Zealand. Globapharm has exclusive rights to Celther Polska’s suite of Products.
RAPID DIAGNOSTIC MEDICAL TESTS
February, 2022
Globapharm is pleased to announce its distribution agreement with Nanorepro AG. The distribution agreement provides Globapharm exclusive rights for the Australian and New Zealand markets to commercialise Nanorepro AG’s range of innovative rapid diagnostic medical tests. Nanorepro AG is the market leader in providing COVID-19 diagnostic tests in Germany.
Bactimum: A UNIQUE PROBIOTIC
October, 2021
Globapharm is pleased to announce its distribution agreement with Vesale Pharma. The distribution agreement gives Globapharm exclusive rights to the suite of Products produced by Vesale Pharma in Australia and New Zealand, with its innovative and unique probiotic Bactimum, a key initial focus for both parties.
Energast FOR IBS
March, 2020
Globapharm is pleased to announce its agency agreement for Energast with Bioton S.A, a Poland based innovative biotech organisation. Energast is best in class and helps patients managing conditions such as, but not limited to, IBS (Irritable Bowel Syndrome).
Globapharm is actively seeking an appropriate partner to bring this product to market.
